The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing
Tianyu Guo(Queen Mary University of London), Yong‐Jie Lu(Queen Mary University of London), Glenda Scandura(Queen Mary University of London), Lei Xu(Soochow University), Prabhakar Rajan(University College London Hospitals NHS Foundation Trust), Jiaying Lu(Fudan University), Jonathan Shamash(Queen Mary University of London), Greg Shaw(Sir Charles Gairdner Hospital), Xueying Mao(Shanghai Jiao Tong University), Constantine Alifrangis(Wellcome Sanger Institute), Karen Tipples(Barts Health NHS Trust), Edwina Burke(Queen Mary University of London), Alistair Grey(Barts Health NHS Trust), Ninghan Feng(Wuxi No.2 People's Hospital), Jacek Marzec(Queen Mary University of London), Elzbieta Stankiewicz(Queen Mary University of London), Daniel M. Berney(Queen Mary University of London), R.T.D. Oliver(St Bartholomew's Hospital), Caitlin R. Davies(Queen Mary University of London), Wen Wang(Second Military Medical University), Liang Wang(Medical College of Wisconsin), Yang Wang(Sichuan University), Jing Jia(First Affiliated Hospital of Xi'an Jiaotong University), Thomas Powles(Queen Mary University of London), John Hines(Barts Health NHS Trust), Sakunthala C. Kudahetti(Queen Mary University of London), Manish Kohli(Mayo Clinic in Arizona)
Cited by 64
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Characterization of human plasma-derived exosomal RNAs by deep sequencing
|BMC Genomics|2013|1.1k
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial
|The Lancet|2005|447
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
|Journal of Clinical Oncology|1997|334